Overview

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Radiation therapy using holmium Ho 166 DOTMP may damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy using holmium Ho 166 DOTMP plus melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Melphalan
Criteria
DISEASE CHARACTERISTICS: Multiple myeloma with one of the following: Complete or partial
response to initial chemotherapy OR Primary refractory disease OR Chemotherapy responsive
relapse Undergoing autologous or syngeneic peripheral blood stem cell transplantation No
myeloma in refractory relapse

PATIENT CHARACTERISTICS: Age: 18 to physiologic 65 Performance status: Zubrod 0-2 Life
expectancy: Not severely limited by concurrent illness Hematopoietic: Not specified
Hepatic: Bilirubin less than 2 mg/dL SGPT less than 4 times normal Renal: Creatinine
clearance at least 30 mL/min Cardiovascular: No uncontrolled arrhythmias or symptomatic
cardiac disease Pulmonary: No symptomatic pulmonary disease FEV1, FVC, and DLCO at least
50% of predicted Other: Not pregnant or nursing Fertile patients must use effective
contraception HIV negative No spinal cord compression

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: Prior external beam
radiotherapy not to exceed 30 Gy to spinal cord or greater than 20% of bone marrow volume
Surgery: Not specified Other: At least 1 month since prior bisphosphonates No other
concurrent experimental agents